Illumina, Inc. ILMN recently introduced its second FDA-regulated and CE-IVD marked next-generation sequencing (NGS) system — NextSeq 550Dx. The instrument has been designed to deliver the power of ...
Both FDA-regulated and CE-in vitro diagnostic (IVD) marked, the NextSeq 550Dx instrument enables clinical laboratories to develop and perform a wide range of applications, from NGS IVD assays using ...
Illumina CEO Francis deSouza on Monday unveiled two new sequencing systems, NextSeq 2000 (pictured) and NextSeq 1000, both designed to meet growing demand for clinical genomic data at reduced cost, as ...
SAN DIEGO--(BUSINESS WIRE)--Illumina, Inc. (NASDAQ: ILMN) further demonstrated its commitment to making genomics more accessible for the potential benefit of patients today with a series of technology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results